Bioavailability file: Rivastigmine tartrate

Fabad Journal of Pharmaceutical Sciences

Volumn 30, Issue 3, 2005, Pages 150-157

  Mutlu, N Başaran ^a   Deǧim, Zelihagül ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

Alzheimer disease; Bioavailability; Carbamate derivative; Parkinson's disease; Pharmacokinetics; Rivastigmine

Indexed keywords

EID: 77952904210     PISSN: 13004182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. John B, Standridge MD. Pharmacotherapeutic approaches to the treatment of Alzheimer's disease, Clin. Ther., 26(5), 615-630, 2004.
2. Scarpini E, Scheltens P, Feldmen H. Treatment of Alzheimer's disease: current status and new perspectives, Lancet Neuro., 2, 539-547, 2003. (Pubitemid 36994993)
3. Williams BR, Nazarians A, Gill MA. A review of rivastigmine: a reversible cholinesterase inhibitor, Clin. Ther., 25(6), 1651-1653, 2003. (Pubitemid 36801939)
4. Farlow M, Lilly LM. Rivastigmine: an open labeled, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years, BMC Geriatrics, 5(3), 1-7, 2005. (Pubitemid 40317958)
5. Polinsky RJ. Clinical pharmacology of rivastigmine: a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, Clin. Ther., 20(4), 634-647, 1998.
6. Agid Y, Dubois B, Anand R, Gharabawi G. Efficacy and tolerability of rivastigmine in patients with dementia of the alzheimer type, Curr. Ther. Res., 59(12), 833-845, 1998. (Pubitemid 29014307)
7. Yüksel N. Alzheimer hastaliǧinin ilaçla tedavisi, Klinik Psikiyatri, 3, 137-141, 2000.
8. Ercan S. Alzheimer hastaliǧi tedavisinde kullanilan kolinesteraz inhibitörleri, Demons, 2, 5-9, 2002.
9. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial, Mov. Dis., 16(6), 1171-1174, 2001.
10. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschi G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poeve W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R. Rivastigmine for dementia associated with Parkinson's disease, N. Engl. J. Med, 351(25), 2509-2519, 2004. (Pubitemid 39468392)
11. Leroi I, Collins D, Marsh L. Non-dopaminergic treatment of cognitive impairment and dementia in Parkinson's disease, J. Neuro. Sci., 248 (1-2), 104-114, 2006. (Pubitemid 44647299)
12. Parry AMM, Scott RB, Palace J, Smith S, Matthews PM. Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine, Brain, 126, 2750-2760, 2003. (Pubitemid 37463093)
13. Tse FLS, Laplanche R. Absorption, metabolism and disposition of [14CJSDZ ENA 713, an acetyl-cholinesterase inhibitor, in minipigs following oral, intravenous, and dermal administration, Pharm. Res., 15-10, 1614-1620, 1998.
14. Physicians Desk Reference, 58th ed., 2252-2260, 2004.
15. Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors, Clin. Pharmacokinet., 41(10), 719-739, 2002. (Pubitemid 34948194)
16. Hsiung GYR. Current therapy: a review of the cholinesterase inhibitors, BC Med. J., 47(7), 1-5, 2004.
17. Guideline for cognitive impairment: dementia diagnosis to management, Alberta Clinical Practice Guidelines, 2005.
18. Farlow MR. Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galantamine, Clin. Ther., 23-Suppl.A, A13-A24, 2001.
19. Merck Index, 13th ed.,1480, 2001.
20. Rao BM, Srinivasu MK, Kumar KP, et al. A stability indicating LC method for rivastigmine hydrogen tartrate, J. Pharm. Biomed. Anal, 37, 57-63, 2005. (Pubitemid 40138716)
21. Enz A, Chappuis A, Dattler A. A simple rapid and sensitive method for simultaneous determination of rivastigmine and its major metabolite NAP 226-90 in rat brain and plasma by reversed-phase liquid chromatography coupled to electrospray ionisation mass spectrometry, Biomed. Chromatogr., 18, 160-166, 2004. (Pubitemid 38584833)
22. Poimmer F, Frigola R. Quantitative determination of rivastigmine and its major meatbolite in human plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry, J. Chromatogr. B, 784,301-313, 2002.
23. Lucangioli SE, Tripodi V, Masrian E, Scioscia SL, Carducci CN, Kenndler E. Enantioselective separation of rivastigmine by capillary electrophoresis with cyclodextrines, J. Chromatogr. A, 1081, 31-35, 2005. (Pubitemid 40799226)
24. Srinivasu MK, Rao BM, Reddy BSS, Kumar PR, Chandrasekhar KB, Mohakhud PK. A validated chiral liquid chromatographic method for the enantiomeric separation of rivastigmine hydrogen tartrate, a cholinesterase inhibitor, J. Pharm. Biomed. Anal, 38, 320-325, 2005.
25. Kavalirova A, Pospisilova M, Karlicek R. Enantiomeric analysis of rivastigmine in pharmaceuticals by cyclodextrin-modified capillary zone electrophoresis, Anal. Chim. Acta, 525, 43-51, 2004. (Pubitemid 39330385)
26. Mustazza C, Borioni A, Del Giudice MR. Synthesis and cholinesterase activity of phenylcarbamates related to rivastigmine, a therapeutic agent for Alzheimer's disease, Eur. J. Med. Chem., 37, 91-109, 2002. (Pubitemid 34164676)
27. Doraiswamy PM, Krishan KRR, Anand R, Shon H, Danyluk J, Hartman RD, Veach J. Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits?, Prog. Neuropsychopharmacol Biol. Psychiatry, 26, 705-712, 2002. (Pubitemid 34615976)
28. Enz A, Gentsch C. Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain, Neuropharm., 47, 408-413, 2004. (Pubitemid 38953232)
29. Eskander MF, Nagykery NG, Leung EY, Khelghati B, Geula C. Rivastigmine is a potent inhibitor of acetyl-and butyrylcholinesterase in Alzheimer's plaques and tangles, Brain Res., 1060, 144-152, 2005. (Pubitemid 41483599)
30. Anand R. Cholinesterase inhibitors in the treatment of dementia, Eur. Neuropsychopharm., 10(Suppl 3), 192-193, 2000.
31. Giacobini E, Spiegel R, Enz A, Veroff AE, Cutler NR. Inhibition of acetyl- and butyrylcholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit, J. Neural. Transm, 109, 1053-1065, 2002. (Pubitemid 34762344)
32. Reichman WE. Current pharmacologic options for patients with Alzheimer's disease, Ann. Gen. Hosp. Psych., 2(1), 1-14, 2003.
33. McKeith I, Del Ser T, Spano PF, Emre M, Wesnas K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study, Lancet, 356, 2031-2036, 2000. (Pubitemid 32009817)
34. Kumari V, Aasen I, Ffytche D, Williams SCR, Sharma T. Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, doubleblind fMRI study, Neuroimage, 29, 545-556, 2006. (Pubitemid 43063311)
35. Ilicali E.Vasküler risk faktörleri bulunan alzheimer hastalarmda Exelon® 'un etkinlik ve güvenilirlik analizi, Demans, 1, 121-129, 2001.
36. www.drugs.com/rivastigmine tartrate
37. Wolfson C, Oresmus M, Shukla V, Momoli F, Demers L, Perrault A, Moride Y. Donapezil and rivastigmine in the treatment of Alzheimer's disease: a best evidence synthesis of the published data on their efficacy and cost-effectiveness, Clin. Ther., 24(6), 862-885, 2002. (Pubitemid 34734735)
38. Cutler NR, Hossain M, Mcdonald C, Pommier F, Sedek G, Jhee SS, Sramek JJ. Pharmacokinetics of rivastigmine and its metabolite in patients with Alzheimer's disease, Biol Psychiat, 47, 161S, 2000.
39. Gobburu JV, Tammara V, Lesko L, et al. Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease, J. Clin. Pharmacol., 41, 1082-1090, 2001. (Pubitemid 32880136)
40. www.exelon.com/hcp/treating/tolerability.jsp
41. Deǧim Z, Ünal N, Eşsiz D, Abbasoǧlu U. The effect of various liposome formulations on insulin penetration across Caco-2 cell monolayer, Life Sci, 75, 819-2827, 2004. (Pubitemid 39349268)
42. Deǧim Z, Ünal N, Eşsiz D, Abbasoǧlu U. Caco-2 cell culture as a model for famotidine absorption, Drug Del, 12, 27-33, 2005.
43. Alavijeh MS, Chishty M, Qaiser MZ, Palmer AM. Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery, NeuroRX, 2(4), 554-571, 2005.